Anti-prolactin autoantibodies in paediatric systemic lupus erythematosus patients. 2001

F Blanco-Favela, and Quintal MaG, and A K Chavez-Rueda, and A Leaños-Miranda, and R Berron-Peres, and V Baca-Ruiz, and C Lavalle-Montalvo
Hospital de Pediatria, Centro Medico Nacional Siglo XXI, IMSS, Mexico.

The aim of this study was to determine the frequency of anti-prolactin autoantibodies and the relationship among anti-prolactin autoantibodies, serum prolactin (PRL) levels and lupus activity in paediatric patients with systemic lupus erythematosus (SLE) using a transversal study. One-hundred and three consecutive paediatric SLE patients were tested for serum anti-PRL autoantibodies and PRL levels. Clinical disease activity was scored using the SLEDAI index. Anti-PRL autoantibodies were measured by means of gel filtration. The frequency of anti-PRL autoantibodies was 6.7% (7/103), on the basis of the amount of immunoreactive PRL eluted in molecular weight fraction corresponding to IgG (150 kDa). No anti-PRL autoantibodies were found in normoprolactinaemic patients. By contrast, 21.8% (7/32) hyperprolactinaemic patients (hPRL) had anti-PRL autoantibodies. There was a correlation between anti-PRL autoantibody and serum levels of PRL (r(s) = 0.98, P = 0.0001). Lupus activity was present in 64/103 (62.1%) patients, without a significant difference in the frequency of anti-PRL autoantibodies when compared to inactive lupus (7.8 vs 5.1%, P > 0.05). Higher levels of serum PRL were associated with lupus activity regardless of other variables (39.6% vs 17.9%, P = 0.05). Patients with anti-PRL autoantibodies had higher levels of serum PRL than those without anti-PRL autoantibody (41.85 vs 17.77 ng/ml, P = 0.01) and significantly different frequency of hPRL (100 vs 26%, r = 0.4531, P < 0.001). We have identified a subset of paediatric SLE patients with hPRL and anti-PRL autoantibodies. Anti-PRL autoantibodies were associated with hPRL state and antibody titres correlated positively with serum PRL levels. These data suggest that anti-PRL autoantibodies could be responsible for hPRL in a subset of SLE patients. An increase in serum PRL levels proved to be related to lupus activity, but there was no statistical relationship between anti-PRL autoantibodies and lupus activity.

UI MeSH Term Description Entries
D006966 Hyperprolactinemia Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8) Prolactin Hypersecretion Syndrome,Prolactin, Inappropriate Secretion,Hyperprolactinaemia,Inappropriate Prolactin Secretion,Inappropriate Prolactin Secretion Syndrome,Hyperprolactinemias,Hypersecretion Syndrome, Prolactin,Inappropriate Secretion Prolactin,Prolactin Secretion, Inappropriate,Secretion Prolactin, Inappropriate,Secretion, Inappropriate Prolactin,Syndrome, Prolactin Hypersecretion
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity

Related Publications

F Blanco-Favela, and Quintal MaG, and A K Chavez-Rueda, and A Leaños-Miranda, and R Berron-Peres, and V Baca-Ruiz, and C Lavalle-Montalvo
January 1998, Lupus,
F Blanco-Favela, and Quintal MaG, and A K Chavez-Rueda, and A Leaños-Miranda, and R Berron-Peres, and V Baca-Ruiz, and C Lavalle-Montalvo
January 2001, Lupus,
F Blanco-Favela, and Quintal MaG, and A K Chavez-Rueda, and A Leaños-Miranda, and R Berron-Peres, and V Baca-Ruiz, and C Lavalle-Montalvo
January 2000, Zeitschrift fur Rheumatologie,
F Blanco-Favela, and Quintal MaG, and A K Chavez-Rueda, and A Leaños-Miranda, and R Berron-Peres, and V Baca-Ruiz, and C Lavalle-Montalvo
January 1997, Transactions of the American Clinical and Climatological Association,
F Blanco-Favela, and Quintal MaG, and A K Chavez-Rueda, and A Leaños-Miranda, and R Berron-Peres, and V Baca-Ruiz, and C Lavalle-Montalvo
December 2019, Cells,
F Blanco-Favela, and Quintal MaG, and A K Chavez-Rueda, and A Leaños-Miranda, and R Berron-Peres, and V Baca-Ruiz, and C Lavalle-Montalvo
August 1999, Pharmacology & therapeutics,
F Blanco-Favela, and Quintal MaG, and A K Chavez-Rueda, and A Leaños-Miranda, and R Berron-Peres, and V Baca-Ruiz, and C Lavalle-Montalvo
January 2007, Lupus,
F Blanco-Favela, and Quintal MaG, and A K Chavez-Rueda, and A Leaños-Miranda, and R Berron-Peres, and V Baca-Ruiz, and C Lavalle-Montalvo
January 1984, Journal of clinical immunology,
F Blanco-Favela, and Quintal MaG, and A K Chavez-Rueda, and A Leaños-Miranda, and R Berron-Peres, and V Baca-Ruiz, and C Lavalle-Montalvo
January 2010, Scandinavian journal of rheumatology,
F Blanco-Favela, and Quintal MaG, and A K Chavez-Rueda, and A Leaños-Miranda, and R Berron-Peres, and V Baca-Ruiz, and C Lavalle-Montalvo
April 2009, Rheumatology (Oxford, England),
Copied contents to your clipboard!